B. Riley equity line of credit
Company: Core Scientific
The claim, verbatim
The Company has the right to sell to B. Riley Principal Capital II up to $100,000,000 of common stock shares under an equity purchase agreement entered into on July 20, 2022.
Source (primary)
Core Scientific 8-K filed 2022-10-27 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II ("B. Riley"), pursuant to which, the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock”
How we checked this
Checked on October 11, 2026. The cited source supports every part of this claim.
The 8-K states that on July 20, 2022 the company entered an equity purchase agreement with B. Riley Principal Capital II giving it the right to sell up to $100,000,000 of common stock.
Confirmed in the source:
- Core Scientific entered into an equity purchase agreement with B. Riley Principal Capital II on July 20, 2022
- Under that agreement, Core Scientific has the right to sell to B. Riley up to $100,000,000 of its common stock
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312522270236/d395956d8k.htm) in full (13,474 characters, retrieved September 13, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific 8-K filed 2022-10-27
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II ("B. Riley"), pursuant to which, the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock”
confirms Core Scientific 424B3 filed 2022-10-27
Quote: “the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock”